The large RCTs assessing and comparing new effective options are still required in GCA. Assessment of the value of conventional immunosuppressives, which are more cost-effective options compared to biologic agents, is another research area in GCA treatment especially for developing countries. Upadacitinib seems to be a promising option in GCA. However, more real-life experience is needed to assess the safety of upadacitinib in the elderly population with especially high cardiovascular risk.
Alibaz-Oner et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: